33 results about "Cancer radiation therapy" patented technology

In beam monitoring for detecting annihilation radiations produced by radiation irradiation in radiation therapy for cancer which is performed by irradiating the affected area by X-rays, gamma rays, or particle beams, a detector-shift type combined radiation therapy / PET apparatus is provided with an open PET device that includes a plurality of shiftable multi-ring detector rings; and a radiation irradiation device that is capable of irradiation with a radiation beam through between the detector rings. The apparatus changes the positions of the detector rings, performs irradiation with the radiation beam through between the detector rings, and then performs radiation measurement.

In beam monitoring for detecting annihilation radiations produced by radiation irradiation in radiation therapy for cancer which is performed by irradiating the affected area by X-rays, gamma rays, or particle beams, a detector-shift type combined radiation therapy / PET apparatus is provided with an open PET device that includes a plurality of shiftable multi-ring detector rings; and a radiation irradiation device that is capable of irradiation with a radiation beam through between the detector rings. The apparatus changes the positions of the detector rings, performs irradiation with the radiation beam through between the detector rings, and then performs radiation measurement.

The invention relates to a preparation method of chronic wound dressing, and in particular, relates to a medical dressing loaded with nano silver and bioactive factors and a preparation method thereof. The dressing includes calcium alginate, chitosan or a chitosan derivative as a matrix and is loaded with nano silver antibacterial composition particles and a growth factor EGF. During preparation,calcium alginate core microspheres wrapped with the growth factor are obtained by dropwise adding a sodium alginate solution mixed with the growth factor into a calcium chloride solution. The microspheres are added to a chitosan acetic acid solution to form a polyelectrolyte complex. Then the polyelectrolyte complex is mixed and stirred with nano silver and chitosan, the mixture is added to sodiumalginate, crosslinking and freeze-drying are performed, and finally, the chronic wound dressing loaded with nano silver and the growth factor is formed. The raw materials of the method are cheap andeasy to obtain, the preparation process is stable, the bacteriostatic performance of the chronic wound dressing is good, and the wound repair ability is excellent. The dressing is used for treating various chronic wounds caused by cancer radiotherapy, diabetes, ischemia and the like, and induces cleaning and repairing of the wounds.

A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy.

A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy.

A treatment regimen for a patient undergoing fractionated radiation therapy for a solid tumor type cancer to attain an improvement in one or more of and an optimized balancing of cancer cell radiation sensitization, normal cell radioprotection, selective post-exposure inhibition of cancer cell recovery relative to normal cell recovery, and stabilization of body weight during radiation treatment. The regimen comprises administration of a therapeutic amount of genistein to a patient diagnosed with a solid tumor type cancer throughout an administration period that commences at least five days prior to commencement of fractionated cancer radiation therapy and extends until at least the conclusion of fractionated cancer radiation therapy.

The invention relates to fluorescent microspheres with a carboxyl group-rich surfaces and a synthesis method of the fluorescent microspheres. The surface of the microspheres is rich in carboxyl groups, and fluorescent molecule hybridization is performed due to rare earth coordination on the surface; and the microspheres have a particle size of 0.1-2 [mu]m. The preparation method has good controllability and high reproducibility, and the prepared microspheres have uniform particle size, controllable size, high fluorescence efficiency and stable dispersion in a large range of pH, can be stably dispersed in water, ethanol, acetone, acetonitrile and other solvents, and have non-toxic required raw materials, environmental protection, low price, simple operation and low equipment requirements; the microspheres can be more widely applied to chemistry, biology, material science and other fields, and since the prepared microspheres have higher density of surface carboxyl groups than common carboxylated microspheres, proteins, DNA or other molecules with amino terminals can be immobilized on the microspheres; and it is expected that the microspheres have broad application prospects in the field of biomedicine, especially in fluorescence imaging, cancer radiation therapy, fluorescent labeling, fluorescence analysis and other aspects.

This invention describes the use of a process for treating neoplastic masses, in which the damage to healthy cells surrounding the mass is reduced as compared to current treatment processes, hi embodiments, computer programs are used to prescribe a timed treatment sequence to mitigate some of the deleterious effects of cancer radiation treatment or chemotherapy. By initiating natural cell repair mechanisms with an application of a low dose of radiation to healthy tissue prior to the full cancer treatment, the post-treatment damage to the healthy cells can be reduced.

A method of evaluating a cancer cell sample, the method comprising: a. obtaining a cancer cell sample, optionally a breast cancer cell sample or an ovarian cancer cell sample, after the cancer cells have been exposed to a radiation dose; b. assaying the cancer cell sample to obtain a RNA integrity value and / or a RNA concentration of the cancer cell sample.

The invention provides a production method of tissue compensation glue for cancer radiotherapy, the preparation method comprises the following steps: 1, weighing solid paraffin, low-density polyethylene, a styrene-maleic anhydride copolymer and cross-linked povidone according to the mass ratio of 100: 2: 12-14: 3-7; S2, mixing the styrene-maleic anhydride copolymer with the cross-linked povidone,adding 1,4-dioxane for co-boiling, then cooling to 10-20 DEG C, keeping for 30-40 minutes, then adding hydroxylamine hydrochloride and sodium methoxide to react, then adding methylbenzene for co-boiling for 5 hours, filtering, washing filter residue with diethyl ether and water, and carrying out vacuum drying on the filter residue until the filter residue reaches constant weight to obtain a synergist; S3, mixing and injecting the solid paraffin, the low-density polyethylene and the synergist into a mold, and performing molding and demolding to obtain the tissue compensation adhesive for cancerradiotherapy. The production method provided by the invention has the advantages of simple operation and one-time forming, and the produced tissue compensation glue can be applied to cancer radiotherapy and is good in adhesion to skin.

A nutritional supplement is described that enhances and provides synergistic effects when used in combination with radiotherapy to treat tumors, both reducing tumor size and preventing metastasis. The nutritional supplement has been also found to be effective in reducing negative side effects of concurrent radiotherapy, including inflammation, weight loss, muscle wasting, neutropenia, and loss of cells from the lining of the gut.

The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1):wherein R1, R2, and R4 may be the same or different from one another and represent a hydrogen atom, hydroxy group, or protected hydroxy group, excluding the case where R1, R2, and R4 are all a hydrogen atom, and R3 represents a halogen atom, amino group, carboxyl group, carbamoyl group, cyano group, nitro group, alkyl group having 1 to 6 carbon atoms, alkenyl group having 2 to 6 carbon atoms, or carbonyl group containing an alkoxy group having 1 to 6 carbon atoms).

The invention discloses tissue equivalent filler for cancer radiotherapy. Liquid paraffin and ethylene-butadiene-styrene block copolymer are mixed into mixture; the mixture is heated and cured to obtain the tissue equivalent filler. The ethylene-butadiene-styrene block copolymer in the mixture is 3-20% in mass fraction. The tissue equivalent filler can fitly attach to the body of a patient, and no bubble forms between the filler and the body of the patient; the tissue equivalent filler is good in transparency and allows doctors to see a mark on the body of the patient through the filler, so that radiation dosage is more accurate and more uniform.

Disclosed is a potentiator for radiation therapy which can be used in combination with cancer radiation therapy to increase the radiation dose and can also reduce adverse side effects of the radiation therapy. A potentiator for radiation therapy comprising, as the active ingredient, a pyridine derivative represented by the general formula (1): (1) wherein R<1>, R<2> and R<4> independently represent a hydrogen atom, a hydroxyl group or a protected hydroxyl group, provided that all of R<1>, R<2> and R<4> are not a hydrogen atom; R<3> represents a halogen atom, an amino group, a carboxyl group, a carbamoyl group, a cyano group, a nitro group, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms or a carbonyl group having an alkoxy group having 1 to 6 carbon atoms.

Compositions and methods for the radiological and immunotherapeutic treatment of cancer are provided. Metallic nanoparticles conjugated with an immunoadjuvant are dispersed within a biodegradable polymer matrix that can be implanted in a patient and released gradually. The implant may be configured as, or be a component of, brachytherapy spacers and applicators, or radiotherapy fiducial markers. The composition may be combined with marginless radiotherapy, allowing for lower doses of radiation and enhancing the immune response against cancer, including at non-irradiated sites.

The invention discloses cancer radiation therapy image guiding equipment. The cancer radiation therapy image guiding equipment includes an annular rack, a therapeutic head and a plurality of X-ray imaging systems, wherein the therapeutic head and the X-ray imaging systems are mounted on the outer circumferential side face of the annular rack; and an EPID image collection system panel receiver anda plurality of X-ray panel receivers are mounted on the inner circumferential side face of the annular rack, wherein the EPID image collection system panel receiver and the therapeutic head are oppositely arranged at the two sides of the annular rack respectively, the EPID image collection system panel receiver is used for receiving rays emitted by the therapeutic head, the X-ray panel receivers and the corresponding X-ray imaging systems are oppositely arranged at the two sides of the annular rack respectively, and the X-ray panel receivers are used for receiving rays emitted by the X-ray imaging systems. According to the cancer radiation therapy image guiding equipment, EPID image collection imaging and the X-ray imaging systems are integrated, 2D / 2D image guiding and 3DCBCT image guiding are finished rapidly, real-time image guiding and dose guiding are achieved, image quality and collection time are both taken into account, clinical therapeutic efficiency is improved, a combined therapy of the cancer radiation therapy image guiding equipment and an after-loading therapy machine is achieved, and meanwhile, internal irradiation and external irradiation are conducted synchronouslyor independently.

The embodiment of the invention discloses a tissue equivalent filler for cancer radiotherapy. The filler comprises a mixture obtained by mixing liquid paraffin, an antibacterial agent and a block copolymer, the mixture is heated and cured to obtain the tissue equivalent filler, the mass fraction of the block copolymer in the mixture is 2-10%, and the number-average molecular weight of the block copolymer is 50 000-300 000. Compared with the prior art, the tissue equivalent filler for cancer radiotherapy has the beneficial effects that the antibacterial and bactericidal effects are good; the contact part of the tissue equivalent filler and the body of a patient is not prone to be infected; and the advantages that oxidation resistance is achieved, the viscosity is high, the application property is good, the attachment is firm, slipping is not prone to occur, the flexibility is excellent, the tensile strength is high, the permanent deformation is not prone to occur, and the like are achieved.

A method and system are provided. The method includes condensing, by a processor, an original voxel-beamlet matrix stored in a memory device into a reduced dataset for proton beam simulation and therapy. The original voxel-beamlet matrix has a row for each of a plurality of voxels in a three-dimensional patient volume and a column for each of a plurality of radiation beamlets. The condensing step includes determining protobeams to be extracted from the original voxel-beamlet matrix. The protobeams are columns (i) selected from the original voxel-beamlet matrix based on comparisons performed between the columns in the original voxel-beamlet matrix or (ii) created by combining at least some of the columns in the original voxel-beamlet matrix, in a matrix condensing process. The condensing step further includes extracting the protobeams from the original voxel-beamlet matrix. The condensing step also includes storing the protobeams as the reduced dataset in the memory device.

The invention discloses cancer radiation therapy equipment. The cancer radiation therapy equipment structurally comprises a machine body, a display screen, a radiation therapy opening, a detection head, a bed body, a relieving device, an adjusting bed board and a fixing support saddle. After improvement, when the cancer radiation therapy equipment is used, a pressing concave block can be tightly attached to the back of a patient, an air bag is stressed to drive the pressing concave block to move up and down, and the pressing concave block can bounce up and down to knock the back of the patient. The cancer radiation therapy equipment can transfer the attention of a patient, alleviate the tension of the patient during radiotherapy, and transmit hot air to the back of the patient through cooperation of heat transfer dispersion plates and dispersion through holes, so that the limbs of the patient are not cold and stiff during radiotherapy, the incident angle of radiated rays is accurate, and cancer cells in the body of the patient can be effectively subjected to radiation treatment.

The invention provides a pharmaceutical composition comprising (a) a compound of the formula (1), wherein R1, R2, R3 and R4 are substituents, at least one of which contains a carborane cluster; and M is selected from two hydrogen ions and one or two metal ions, wherein any metal ions present are charge-balanced by one or more counter ions; and (b) a vehicle comprising: (i) dimethylacetamide as solvent; and (ii) a co-solvent comprising one or more of tetraglycol; propylene glycol; polyethylene glycol; and a non-ionic surfactant. The pharmaceutical compositions are useful as radiation sensitizers in radiation treatment of cancers.